The lifecycle of a medical consensus is often a protracted, winding journey. In an ideal healthcare ecosystem, when rigorous clinical trials reveal that a widely prescribed pharmaceutical is less effective than previously understood—or carries risks that heavily outweigh its therapeutic benefits for specific populations—practice patterns shift swiftly. Researchers publish their findings, peer reviewers validate the methodology, medical associations rewrite their clinical guidelines, and practicing physicians alter their prescription pads.
Yet, the reality of modern clinical practice is far more complicated.
Time and again, health services research demonstrates a profound gap between the emergence of safety warnings and actual changes in patient care. Even when prestigious panels—such as the American Geriatrics Society, the U.S. Preventive Services Task Force, or the Food and Drug Administration—issue stern warnings, black-box advisories, or inclusions on lists of potentially inappropriate medications, prescribing habits remain stubbornly entrenched.
This phenomenon, widely studied by health policy experts and geriatricians, is driven by what medical professionals describe as clinical inertia and deeply ingrained behavioral habits. As geriatrician Dr. Michael Steinman of the University of California-San Francisco and co-director of the U.S. Deprescribing Research Network succinctly notes, medications are remarkably similar to marine barnacles. They are exceptionally easy to initiate, but notoriously difficult to remove once established in a patient’s daily routine.
Recent comprehensive studies focusing on three widely utilized pharmaceutical interventions among older Americans—benzodiazepines, antibiotics for uncomplicated diverticulitis, and routine low-dose aspirin for primary cardiovascular prevention—underscore the stubborn persistence of outdated medical practices. These cases reveal not only the challenges of disseminating modern medical knowledge, but also the systemic hurdles patients and providers face when attempting to safely de-escalate treatment regimens.
The Benzodiazepine Dilemma: Lingering Risks for Vulnerable Populations
The systemic risks associated with benzodiazepines—a class of sedative-hypnotic medications that includes Valium, Xanax, and Ativan, alongside related "Z-drugs" like Ambien and Lunesta—have been documented by the scientific community for more than two decades. Prescribed primarily to treat chronic insomnia and generalized anxiety disorders, these agents offer patients immediate, tangible relief from distressing symptoms.
However, the pharmacological profile of these drugs makes them exceptionally hazardous for older adults, whose physiological clearance rates and sensitivities differ significantly from younger populations. According to Dr. Mark Olfson, a psychiatrist and epidemiologist at Columbia University, benzodiazepines frequently impair balance, physical coordination, and cognitive processing. In older adults, these impairments directly translate to severe clinical outcomes, including injurious falls, bone fractures, and motor vehicle accidents. Furthermore, when combined with opioid analgesics for pain management, benzodiazepines significantly elevate the risk of fatal respiratory depression and overdose.
Beyond acute injury risks, long-term administration fosters physiological dependence. Discontinuing the medication abruptly can trigger severe, prolonged withdrawal symptoms, complicating efforts to safely transition patients to non-pharmacological therapies like cognitive behavioral therapy for insomnia.
Despite these recognized hazards, recent nationwide evaluations of prescribing trends reveal a troubling plateau in reduction efforts. In an examination published in the Annals of Internal Medicine, Olfson and his research team tracked national prescribing data and found that while the rate of individuals aged 65 and older filling prescriptions for benzodiazepines dropped modestly from approximately 14% in 2015 to 11.5% in 2024, this downward trajectory stalled significantly around the onset of the COVID-19 pandemic in 2020.
More alarmingly, prescribed usage actually ticked upward among the most vulnerable demographic: adults aged 75 and older, rising from 12% in 2020 to roughly 13% four years later. Concurrently, pharmacy dispensing rates within long-term care facilities more than doubled during the observation period. Compounding the risk, approximately one-third of all users maintained continuous therapy for longer than six months, dramatically amplifying their risk of dependence and cognitive decline.
Public health experts emphasize that patients should never attempt to discontinue benzodiazepines independently or abruptly due to the severe physiological risks of unmonitored withdrawal. Instead, medical authorities advocate for supervised, gradual tapering protocols managed by qualified clinicians over a period of many weeks or months.
Antibiotic Overuse: The Unyielding Grip of Routine Diverticulitis Treatment
A parallel narrative of entrenched clinical habit unfolds within gastroenterology and acute care settings, specifically concerning the management of colonic diverticulitis—an inflammatory or infectious condition affecting small herniations in the colon wall.
For decades, standard medical dogma dictated that acute diverticulitis required immediate, aggressive treatment with broad-spectrum systemic antibiotics, predominantly fluoroquinolones such as Cipro and Levaquin, or amoxicillin-clavulanate combinations like Augmentin. According to Jesse Sutton, a clinical pharmacist and researcher at the Minneapolis Veterans Affairs healthcare system, this approach was rarely questioned. Antibiotics are historically viewed as foundational, lifesaving interventions; consequently, the prevailing clinical mindset operated on the premise that when in doubt, aggressive antibiotic deployment was always the safest path.
That clinical consensus began to shift significantly in 2015. Following accumulating evidence from randomized controlled trials, the American Gastroenterological Association formally recommended against the routine, automatic prescription of antibiotics for "uncomplicated" diverticulitis—a classification that accounts for the vast majority of patient presentations. Other prominent medical and surgical societies rapidly followed suit, publishing updated clinical guidelines.
The rationale behind the guideline shift was clear: robust clinical trials demonstrated that for uncomplicated cases, antibiotic therapy had little to no measurable impact on overall mortality rates, the necessity for emergent surgical intervention, disease complications, or long-term recurrence rates. As Sutton observed, the drugs did not materially improve clinical recovery metrics for the average patient.
Simultaneously, the broader consequences of unnecessary antimicrobial exposure became increasingly apparent. Adverse drug events stemming from systemic antibiotics account for a substantial volume of emergency department visits each year, driven by acute gastrointestinal distress such as severe nausea, vomiting, and debilitating diarrhea. Furthermore, indiscriminate antibiotic use sharply elevates a patient’s susceptibility to virulent, potentially life-threatening Clostridioides difficile infections. On a macro-level, rampant overprescribing accelerates the development of antimicrobial resistance, which the World Health Organization has classified as a critical, top-tier global public health threat.
Anticipating a dramatic shift in clinical behavior, Sutton and a team of researchers analyzed treatment records across 70,000 outpatient and inpatient visits spanning 120 Department of Veterans Affairs healthcare facilities over a ten-year period. Their findings, published recently in the Annals of Internal Medicine, starkly contradicted expectations. Despite clear, widely disseminated guideline updates, antibiotic prescription rates for uncomplicated diverticulitis remained nearly universal, holding steady at 97% of clinical encounters. Clinical evidence suggests that many of these patients would have achieved identical recovery outcomes utilizing conservative supportive care, such as short-term analgesic use with acetaminophen and a temporary clear liquid diet.
This pattern of overuse extends far beyond diverticulitis. Similar prescribing inertia frequently affects the management of asymptomatic bacteriuria—bacteria detected in routine urine tests that cause zero clinical symptoms—and upper respiratory tract infections that are viral in origin and fundamentally unresponsive to antibacterial agents. Health system analysts suggest that when clinicians reflexively prescribe antibiotics in these scenarios, patients should feel empowered to engage in collaborative dialogue by politely asking for the specific diagnostic rationale before filling the prescription.
The Aspirin Paradox: Navigating Primary Prevention and Bleeding Risks
While prescription medications involve direct physician interaction, over-the-counter remedies present a unique set of challenges regarding consumer self-management and public health messaging. Aspirin occupies a distinctive niche in American medicine. Inexpensive and accessible without a prescription, millions of older adults have historically initiated daily aspirin regimens independently, operating under the widespread assumption that a routine low-dose tablet serves as a universal safeguard against cardiovascular disease.
The clinical consensus regarding aspirin is nuanced and depends heavily on the distinction between secondary and primary prevention. For individuals who have already experienced a major cardiovascular event—such as a myocardial infarction, an ischemic stroke, or surgical interventions like coronary artery stenting or bypass grafting—robust clinical trial data confirms that daily low-dose aspirin ("secondary prevention") substantially reduces the recurrence of vascular events and improves long-term survival.
However, for "primary prevention"—individuals with no prior history of cardiovascular events who are attempting to stave off a first-time heart attack or stroke—the medical guidelines underwent a profound revision. In 2019, the American College of Cardiology and the American Heart Association issued joint clinical guidelines advising against the routine use of aspirin for primary cardiovascular prevention in adults aged 70 and older. Shortly thereafter, the U.S. Preventive Services Task Force strengthened these cautions, extending the recommended threshold against primary aspirin therapy to adults aged 60 and older.
Large-scale randomized controlled trials revealed that the cardiovascular benefits of prophylactic aspirin for primary prevention were exceedingly modest and largely offset by severe clinical harms. Most notably, chronic aspirin therapy significantly increases the cumulative risk of gastrointestinal bleeding. As Dr. Timothy Anderson, an internal medicine physician at the University of Pittsburgh and co-director of its Prescribing Wisely Lab, explains, the physiological susceptibility to hemorrhagic events increases progressively as individuals age. In rarer, more catastrophic cases, aspirin can provoke intracranial hemorrhaging.
Recent investigations suggest that public health messaging is gradually penetrating the broader population. A study co-authored by Anderson and published in JAMA examined data from the National Health and Nutrition Examination Survey, revealing that the prevalence of aspirin use for primary prevention declined substantially between 2011 and 2023. Nevertheless, despite years of updated warnings, more than a third of adults aged 70 and older reported ongoing, routine aspirin use without a documented history of cardiovascular disease.
Experts emphasize important clinical caveats. A carefully selected subset of older adults with exceptionally high, individualized risk factors for cardiovascular disease may still derive a net benefit from primary aspirin therapy. Conversely, complex clinical evidence indicates that older patients who are already taking chronic aspirin may face an elevated risk of cardiovascular events if they discontinue the medication abruptly without medical oversight.
Consequently, health authorities urge patients to initiate a formal review with their primary care physician to re-evaluate whether continuing an aspirin regimen remains appropriate given their evolving health profile. While older adults consuming routine aspirin are typically motivated by a proactive desire to safeguard their long-term cardiovascular health, modern medicine now offers far superior, safer, and more targeted pharmacological strategies—such as modern antihypertensive agents and high-efficacy statin therapies—to manage vascular risk without the compounding hazard of bleeding complications.
Addressing Systemic Inertia in Modern Healthcare
The persistence of inappropriate or outdated medication use among older populations highlights a systemic vulnerability in how clinical knowledge is translated into everyday medical practice. Overcoming clinical inertia requires a multifaceted approach involving enhanced medical education, robust clinical decision-support tools integrated within electronic health record systems, and structured interdisciplinary collaborations between physicians, clinical pharmacists, and geriatric specialists.
Ultimately, navigating the complexities of modern pharmacology requires a shift away from additive medical thinking toward a culture of thoughtful, supervised de-prescribing. By fostering open, proactive communication between patients and their healthcare teams, the medical community can better align routine clinical practice with contemporary evidence, ensuring that pharmaceutical therapies genuinely serve to enhance, rather than compromise, the health and well-being of older adults.
Leave a Reply